# NURE-Combo (NCT04876313)

> An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)

No report yet. It can be ordered.

- Drugs tested: nivolumab plus nab-paclitaxel
- Indication: muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04876313
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: IRCCS San Raffaele
- Conditions: Muscle-Invasive Bladder Carcinoma
- Interventions: Nivolumab + Nab-paclitaxel; Nivolumab
- Enrollment: 29
- Primary outcome: Pathological complete response

## Indexed commentary on NURE-Combo so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 43 posts on X
- 2 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nure-combo-nct04876313

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04876313", "email": "<work email>"}; the inbox owner confirms by the emailed link.